Pharmafile Logo

News and Press Releases

AiCuris Received €15m Milestone Payment from Licensing Partner MSD Following EMA Approval of PREVYMIS for Prevention of CMV Infection in High-Risk Adult Kidney Transplant Recipients

PREVYMIS now approved in the US and Europe for prophylaxis of Cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]) EMA approval...

Category: Pharmaceutical
Posted: January 9, 2024

AiCuris Anti-Infective Cures
info@aicuris.com
Friedrich-Ebert-Str. 475 / Building 302 42117 Wuppertal Germany

MSD’s WELIREG▼(belzutifan) made available for the treatment of eligible adults with von Hippel-Lindau (VHL) disease in Scotland

Scotland is the first European country to accept belzutifan as a treatment for adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL-associated renal cell carcinoma (RCC), central...

Category: Pharmaceutical
Posted: October 9, 2023

Merck
IECustomerrelations@merckgroup.com
1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France

Cancer immunotherapy basket trial leads to NICE recommendation for MSD’s KEYTRUDA (pembrolizumab) as a treatment option for adults with previously treated endometrial, biliary, colorectal, gastric and small intestine cancer with microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR)

The results from the basket trial show that pembrolizumab monotherapy demonstrates clinically meaningful data to patients with MSI-H or dMMR solid metastatic tumours, across the five tumour sites evaluated, with...

Category: Clinical Trials
Posted: August 22, 2023

Merck
IECustomerrelations@merckgroup.com
1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France